Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

BMC Endocrine Disorders

Volumn 17, Issue 1, 2017, Pages

  Wysham, Carol H ^a   Lefebvre, Patrick ^b   Pilon, Dominic ^b   Ingham, Mike ^c   Lafeuille, Marie Hélène ^b   Emond, Bruno ^b   Kamstra, Rhiannon ^b   Chow, Wing ^d   Pfeifer, Michael ^c   Duh, Mei Sheng ^e  

^a Rockwood Clinic   (United States)

^b Groupe d analyse   (Canada)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d JOHNSON AND JOHNSON   (United States)

^e ANALYSIS GROUP   (United States)

Author keywords

Blood pressure; Canagliflozin; Dipeptidyl peptidase 4 inhibitor; HbA1c; Type 2 diabetes mellitus; Weight loss

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ALOGLIPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; RENIN INHIBITOR; SAXAGLIPTIN; SITAGLIPTIN; VASODILATOR AGENT; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; QUALITY CONTROL; QUALITY MEASURE ACHIEVEMENT; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; YOUNG ADULT; BODY WEIGHT LOSS; ELECTRONIC HEALTH RECORD; TREATMENT OUTCOME;

ADULT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ELECTRONIC HEALTH RECORDS; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85020437160     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/s12902-017-0180-8     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
2. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123(3):S3-S11.
3. Palmer AJ, Roze S, Valentine WJ, Minshall ME, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE diabetes model. Curr Med Res Opin. 2004;20 Suppl 1:S53-8.
4. Lafeuille M-H, Grittner AM, Gravel J, Bailey RA, et al. Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(1 Suppl):s5-15.
5. Lafeuille M-H, Grittner AM, Gravel J, Bailey RA, et al. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. J Med Econ. 2015;18(2):113-25.
6. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40(Supplement 1):S25-32.
7. National Committee for Quality Assurance (NCQA). HEDIS 2016 - Volume 1: Narrative.; 2016. http://www.ncqa.org/hedis-quality-measurement/hedis-measures/hedis-2016.
8. Bailey RA, Vijapurkar U, Meininger G, Rupnow MFT, et al. Diabetes-related composite quality End point attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Clin Ther. 2015;5:1-10.
9. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, et al. American association of clinical endocrinologists (AACE) and American college of endocrinology (ACE) - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21 Suppl 1:1-87.
10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38(1):140-9.
11. Battise DM. Efficacy and safety of canagliflozin as Add-on therapy to metformin in type 2 diabetes. Clin Diabetes. 2014;32(2):81-6.
12. Seufert J. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, metab syndr obes: targets ther. 2015;8:543-54.
13. Buysman EK, Chow W, Henk HJ, Rupnow MFT. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin. 2015;31(1):137-43.
14. Forst T, Guthrie R, Goldenberg R, Yee J, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467-77.
15. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-92.
16. Nardolillo A, Kane M, Busch R, Watsky J, et al. A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. Clin Med Insights: Endocrinol Diabetes. 2014;7:25-30.
17. Stenlöf K, Cefalu WT, Kim K, Alba M, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-82.
18. Cefalu WT, Leiter LA, Yoon KH, Arias P, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-50.
19. Meckley L, Miyasato G, Kokkotos F, Bumbaugh J, et al. An observational study of glycemic control in canagliflozin treated patients. Curr Med Res Opin. 2015;Online:1-23.
20. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-15.
21. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2015;d:82-91.
22. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). best practice & research. Clin endocrinol metab. 2009;23(4):479-86.
23. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis. J Hypertens. 2016;34(2):167-75.
24. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410-8.
25. Thayer S, Chow W, Korrer S, Aguilar R. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Current medical research and opinion. 32(6):1087-96.
26. United States Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes. https://www.jnj.com/media-center/press-releases/us-fda-approves-invokana-canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes. Accessed 1 June 2017.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
28. Young BA, Lin E, Von Korff M, Simon G, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15-23.
29. Elixhauser A, Steiner C, Kruzikas D. Comorbidity Software Documentation. HCUP Methods Series Report # 2004-1. U.S. Agency for Healthcare Research and Quality. 2004. https://www.hcup-us.ahrq.gov/reports/methods/2004_1.jsp. Accessed 1 June 2017.
30. Cohen J. Statistical power analysis for the behavioral sciences. Toronto: Academic; 1977.
31. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat-Simul Comput. 2009;38(6):1228-34.
32. Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Statistical methods in medical research. 2015;1-21.
33. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007;45(10 Supl 2):S103-7.
34. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-25.
35. Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J clin hypertens (Greenwich, Conn. 2014;16(12):875-82.
36. Grabner M. Demographic and clinical profiles of type 2 diabetes mellitus patients initiating canagliflozin versus DPP-4 inhibitors in a large U.S. Managed care population. J manag care spec pharm. 2015;21(12):1204-12.
37. Bailey RA, Damaraju CV, Martin SC, Meininger GE, et al. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care. 2014;20(1 Suppl):s16-24.
38. Ektare VU, Lopez JMS, Martin SC, Patel DA, et al. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus. Am J Manag Care. 2014;20(10 Suppl):S204-15.
39. Bailey RA, Vijapurkar U, Meininger GE, Rupnow MFT, et al. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Am J Manag Care. 2014;20(13 Suppl):s296-305.
40. Solini A, Penno G, Bonora E, Fondelli C, et al. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events Italian multicenter study. J Am Geriatr Soc. 2013;61(8):1253-61.
41. Heerspink HJL, Desai M, Jardine M, Balis D, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28(1):368-75.
42. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-34.
43. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2015;38(Supplement 1):S1-S94.
44. Janssen Pharmaceuticals Inc. Prescribing information for InvokanaTM (canagliflozin). 2015. https://www.invokana.com/prescribing-information.pdf. Accessed 1 June 2017.